June 7, 2016
The Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States (Perinatal Guidelines) were updated on June 7, 2016.
Appendix B: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy and Table 7: Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy were revised to incorporate new data and publications, Food and Drug Administration drug label changes and new fixed-dose combination formulations.
In Appendix B and Table 7, updates were made to the following drugs: atazanavir, dolutegravir, emtricitabine, fosamprenavir, indinavir, lamivudine, nelfinavir, nevirapine, rilpivirine, ritonavir, saquinavir, stavudine, tenofovir disoproxil fumarate and tipranavir.
For more information, please see What's New in the Guidelines.
|Read the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (PDF)|
|What Did You Expect While You Were Expecting?|
|HIV/AIDS Resource Center for Women|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.